---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015744"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:04:27.002734+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences Q2 net loss $34.9M; cash $325.6M after June public offering

## Summary
- Cash and equivalents $325.6M at June 30, 2022, up from $191M at March 31, 2022; includes $172.6M from June 2022 public offering, funds operations into 2025.
- Net loss $34.9M for Q2 2022 vs $16.5M in Q2 2021; R&D expenses rose to $29.5M from $12.4M on trial costs.
- Positive initial bezuclastinib APEX data: all 11 AdvSM patients achieved ≥50% serum tryptase reduction; no edema, cognitive effects or intracranial bleeding.
- On-track for further APEX data by end of 2022; SUMMIT and PEAK trial data expected in 1H2023.
- Appointed Fang Fang, Ph.D., as VP Biometrics; she brings over 20 years industry experience.

## SEC filing metadata
- accession: 0000950170-22-015744
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017022015744/0000950170-22-015744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017022015744/cogt-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015744
- JSON: https://secwatch.observer/filing/0000950170-22-015744.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015744.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.